Inspire Medical Systems Inc (INSP)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $1.77B
Last updated: Nov 17, 2026 at 11:06 AM ET
Inspire Medical Systems Inc (INSP) Earnings: Report Dates and Results
Inspire Medical Systems (INSP) is expected to report earnings on May 3, 2027. In the quarter ended Sep 30, 2026, Inspire Medical Systems reported EPS of $0.14, above the $0.10 estimate. It beat the EPS estimate in each of the last 26 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INSP has an expected report date of May 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 55.8% below the $1.65 reported for the quarter ended Dec 31, 2025.
INSP Earnings Call
The latest INSP earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 35 quarters below that had an estimate, INSP beat 33 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $206.69M, down 7.9% from $224.50M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.14 | $0.10 | -$0.13 - $0.17 | +40.00% | Beat | -63.2% | 14 | 2 up, 8 down | Nov 2, 2026 | $206.69M |
| Jun 30, 2026 | $0.14 | -$0.22 | -$0.38 - -$0.19 | +163.64% | Beat | -68.9% | 13 | 1 up, 1 down | Aug 3, 2026 | $200.58M |
| Mar 31, 2026 | $0.10 | -$0.26 | -$0.41 - -$0.05 | +138.46% | Beat | 0.0% | 12 | 1 up, 1 down | May 4, 2026 | $204.58M |
| Dec 31, 2025 | $1.65 | $0.68 | $0.61 - $0.73 | +142.65% | Beat | +43.5% | 12 | 5 up, 0 down | Feb 11, 2026 | $269.08M |
| Sep 30, 2025 | $0.38 | -$0.17 | -$0.22 - -$0.03 | +323.53% | Beat | -36.7% | 10 | 1 up, 1 down | Nov 3, 2025 | $224.50M |
| Jun 30, 2025 | $0.45 | $0.20 | $0.12 - $0.27 | +125.00% | Beat | +40.6% | 14 | 0 up, 1 down | Aug 4, 2025 | $217.09M |
| Mar 31, 2025 | $0.10 | -$0.23 | -$0.35 - -$0.15 | +143.48% | Beat | N/A | 14 | 0 up, 1 down | May 5, 2025 | $201.32M |
| Dec 31, 2024 | $1.15 | $0.72 | $0.63 - $0.81 | +59.72% | Beat | +134.7% | 13 | 5 up, 1 down | Feb 10, 2025 | $239.72M |
| Sep 30, 2024 | $0.60 | $0.08 | $0.01 - $0.30 | +650.00% | Beat | N/A | 16 | 0 up, 0 down | Nov 4, 2024 | $203.19M |
| Jun 30, 2024 | $0.32 | -$0.11 | -$0.39 - -$0.02 | +390.91% | Beat | N/A | 17 | 1 up, 1 down | Aug 6, 2024 | $195.88M |
| Mar 31, 2024 | -$0.34 | -$0.67 | -$0.85 - -$0.41 | +49.25% | Beat | N/A | 17 | 0 up, 0 down | May 7, 2024 | $164.01M |
| Dec 31, 2023 | $0.49 | -$0.09 | -$0.35 - $0.18 | +644.44% | Beat | +390.0% | 11 | 6 up, 1 down | Feb 6, 2024 | $192.51M |
| Sep 30, 2023 | -$0.29 | -$0.57 | -$0.80 - -$0.37 | +49.12% | Beat | N/A | 13 | 0 up, 1 down | Nov 7, 2023 | $153.30M |
| Jun 30, 2023 | -$0.41 | -$0.58 | -$0.88 - -$0.40 | +29.31% | Beat | N/A | 13 | 1 up, 0 down | Aug 1, 2023 | $151.09M |
| Mar 31, 2023 | -$0.53 | -$0.70 | -$0.91 - -$0.30 | +24.29% | Beat | N/A | 12 | 0 up, 0 down | May 2, 2023 | $127.90M |
| Dec 31, 2022 | $0.10 | -$0.54 | -$0.87 - -$0.20 | +118.52% | Beat | N/A | 10 | 4 up, 0 down | Feb 7, 2023 | $137.90M |
| Sep 30, 2022 | -$0.60 | -$0.79 | -$0.90 - -$0.48 | +24.05% | Beat | N/A | 10 | 0 up, 0 down | Nov 1, 2022 | $109.19M |
| Jun 30, 2022 | -$0.53 | -$0.63 | -$0.71 - -$0.46 | +15.87% | Beat | N/A | 11 | 0 up, 0 down | Aug 2, 2022 | $91.39M |
| Mar 31, 2022 | -$0.61 | -$0.83 | -$1.04 - -$0.47 | +26.51% | Beat | N/A | 10 | 0 up, 0 down | May 3, 2022 | $69.38M |
| Dec 31, 2021 | -$0.09 | -$0.46 | -$0.60 - -$0.21 | +80.43% | Beat | N/A | 10 | 4 up, 0 down | Feb 8, 2022 | $78.40M |
| Sep 30, 2021 | -$0.38 | -$0.64 | -$0.79 - -$0.44 | +40.63% | Beat | N/A | 11 | N/A | Nov 2, 2021 | $61.69M |
| Jun 30, 2021 | -$0.48 | -$0.66 | -$0.76 - -$0.47 | +27.27% | Beat | N/A | 11 | N/A | Aug 3, 2021 | $52.96M |
| Mar 31, 2021 | -$0.60 | -$0.64 | -$0.90 - -$0.51 | +6.25% | Beat | N/A | 11 | N/A | May 4, 2021 | $40.35M |
| Dec 31, 2020 | -$0.28 | -$0.48 | -$0.77 - -$0.32 | +41.67% | Beat | N/A | 13 | N/A | Feb 23, 2021 | $46.01M |
| Sep 30, 2020 | -$0.39 | -$0.73 | -$0.82 - -$0.63 | +46.58% | Beat | N/A | 13 | N/A | Nov 2, 2020 | $35.84M |
| Jun 30, 2020 | -$0.88 | -$1.14 | -$1.20 - -$0.79 | +22.81% | Beat | N/A | 10 | N/A | Aug 4, 2020 | $12.18M |
| Mar 31, 2020 | -$0.67 | -$0.60 | -$0.74 - -$0.27 | -11.67% | Miss | N/A | 9 | N/A | May 5, 2020 | $21.35M |
| Dec 31, 2019 | -$0.38 | -$0.40 | -$0.55 - -$0.34 | +5.00% | Beat | N/A | 8 | N/A | Feb 25, 2020 | $26.91M |
| Sep 30, 2019 | -$0.34 | -$0.41 | -$0.48 - -$0.35 | +17.07% | Beat | N/A | 7 | N/A | Nov 5, 2019 | $20.86M |
| Jun 30, 2019 | -$0.32 | -$0.43 | -$0.47 - -$0.37 | +25.58% | Beat | N/A | 7 | N/A | Aug 6, 2019 | $18.03M |
| Mar 31, 2019 | -$0.35 | -$0.38 | -$0.47 - -$0.29 | +7.89% | Beat | N/A | 7 | N/A | May 7, 2019 | $16.25M |
| Dec 31, 2018 | -$0.22 | -$0.31 | -$0.39 - -$0.24 | +29.03% | Beat | N/A | 7 | N/A | Feb 26, 2019 | $16.56M |
| Sep 30, 2018 | -$0.22 | -$0.34 | -$0.37 - -$0.33 | +35.29% | Beat | N/A | 5 | N/A | Nov 6, 2018 | $13.05M |
| Jun 30, 2018 | -$0.43 | -$0.48 | N/A | +10.42% | Beat | N/A | 4 | N/A | Aug 7, 2018 | $10.94M |
| Mar 31, 2018 | -$5.05 | -$3.64 | -$5.40 - -$0.32 | -38.74% | Miss | N/A | 3 | N/A | May 4, 2018 | $10.04M |
| Dec 31, 2017 | -$3.46 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 28, 2018 | $9.96M |
| Mar 31, 2017 | -$3.90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2017 | $5.30M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $2.58, up 49.1% from the year before. It was -$7.36 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $2.58 | +49.1% |
| Dec 31, 2024 | $1.73 | N/A |
| Dec 31, 2023 | -$0.74 | N/A |
| Dec 31, 2022 | -$1.64 | N/A |
| Dec 31, 2021 | -$1.55 | N/A |
| Dec 31, 2020 | -$2.22 | N/A |
| Dec 31, 2019 | -$1.39 | N/A |
| Dec 31, 2018 | -$5.92 | N/A |
| Dec 31, 2017 | -$7.36 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,039 | 20 | |
| 2026Q2 | Jun 30, 2026 | 7,170 | 18 | |
| 2026Q1 | Mar 31, 2026 | 7,053 | 19 | |
| 2025Q4 | Dec 31, 2025 | 7,540 | 15 | |
| 2025Q3 | Sep 30, 2025 | 8,342 | 20 | |
| 2025Q2 | Jun 30, 2025 | 8,364 | 18 | |
| 2025Q1 | Mar 31, 2025 | 7,096 | 20 | |
| 2024Q4 | Dec 31, 2024 | 7,363 | 16 |
2026Q3 Earnings Call
Opening remarks
Louisa Smith Moderator Thank you, Dilem. Joining me on today's call are Tim Herbert, Chairman and Chief Executive Officer, and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the three months ended September 30, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of federal securities laws. All forward-looking statements, including without limitation, those relating to our operations, financial results, financial condition, investments in our business, financial and operational outlook for 2026 and future periods, and changes in market access and different aspects of coding or reimbursement, are based upon our current estimates and various assumptions. Forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. For discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission, including our periodic reports on Form 10-K and 10-Q, as well as the Form 10-Q, which we filed this afternoon with the SEC for the quarter ended September 30, 2026. Inspire disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, November 2, 2026. With that, I will turn the call over to Tim. Go ahead.
Tim Herbert Chairman and CEO Thanks, Louisa. Thank you to everyone for joining today's call. To start, the focus of our employees and the physician and care teams we work with is delivering the best possible outcomes for patients. OSA, a largely untreated condition, and the more we learn about it, the clearer it becomes that its impact goes beyond sleep to a patient's underlying health. Our Inspire therapy is the market leader for hypoglossal nerve stimulation treatment for OSA, and we believe that better treatment leads to better sleep, which leads to better health. This belief shapes how we approach everything we do. For the third quarter, we were pleased to deliver revenue and adjusted operating income slightly ahead of our expectations, with another strong quarter of operating cash flow and a 3% sequential revenue increase. Coding has been a central topic this year, so I'll provide an update using the same near-, mid-, and long-term lens we shared in August. In the near term, we continue to work closely with physicians and staff on the new billing procedures. As with any abrupt workflow change, it took time for implanting sites to get comfortable with the new rules.
Frequently Asked Questions About INSP
When is Inspire Medical Systems's next earnings date?
Inspire Medical Systems's next earnings report is expected for May 3, 2027.
Did INSP beat earnings estimates last quarter?
Yes. Inspire Medical Systems reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.10 estimate, a 40.00% surprise.
What EPS do analysts expect from INSP next quarter?
The consensus EPS estimate for Inspire Medical Systems for the quarter ending Dec 31, 2026 is $0.73 from 19 analysts, with estimates from $0.33 to $0.96.
How often does INSP beat earnings estimates?
Inspire Medical Systems beat the EPS estimate in each of the last 26 quarters, with an average surprise of +131.71%.
INSP pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts